News Scholar Rock Holding Corporation

Stocks

SRRK

US80706P1030

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 23/10/2026 BST			5-day change	1st Jan Change
41.49 ^USD	-1.12%		+3.98%	-5.81%

10-08	Scholar Rock Resubmits Apitegromab Application in EU for Spinal Muscular Atrophy	MT
10-08	Scholar Rock Resubmits Apitegromab Marketing Authorisation Application To European Medicines Agency For Treatment Of Children And Adults With Spinal Muscular Atrophy	CI

All News

Mentions Relevance

10-20	Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026	BU
10-16	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
10-08	Scholar Rock Resubmits Apitegromab Application in EU for Spinal Muscular Atrophy	MT
10-08	Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)	BU
10-08	Scholar Rock Resubmits Apitegromab Marketing Authorisation Application To European Medicines Agency For Treatment Of Children And Adults With Spinal Muscular Atrophy	CI
09-25	Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says	MT
09-24	Truist Lifts Price Target on Scholar Rock Holding to $77 From $76, Keeps Buy Rating	MT
09-21	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
09-15	Scholar Rock Shares Fall After Barclays Downgrade	MT
09-15	Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says	MT
09-15	Barclays Downgrades Scholar Rock to Equalweight From Overweight, Adjusts PT to $58 From $55	MT
09-14	Scholar Rock's Early FDA Approval on Spinal Muscular Atrophy Drug Seen as 'Positive Surprise,' UBS Says	MT
09-14	Wedbush Adjusts Price Target on Scholar Rock to $70 From $64, Keeps Outperform Rating	MT
09-14	Scholar Rock Announces FDA Approval of ISEMBYLD (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)	AQ
09-14	Scholar Rock Holding Corporation - Special Call
09-14	Scholar Rock says its first muscle-targeted SMA therapy will cost about $310,000 annually	RE
09-14	Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial	RE
09-14	Truist Raises Price Target on Scholar Rock Holding to $76 From $55, Keeps Buy Rating	MT
09-14	Scholar Rock Gets FDA Approval for Spinal Muscular Atrophy Treatment in Children, Adults; Shares Up Pre-Bell	MT
09-12	Scholar Rock Receives FDA Approval For ISEMBYLD Apitegromab-Mstn For Treatment Of Spinal Muscular Atrophy	CI
09-11	Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)	BU
09-11	Scholar Rock gets first FDA nod for rare muscle-wasting disease (September 11)	RE
09-11	US FDA approves Scholar Rock's muscle weakness drug	RE
09-11	Scholar Rock Gets FDA Approval of Isembyld for Spinal Muscular Atrophy	DJ
09-10	Scholar Rock Holding Corporation Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-10-2026 09:20 AM